Based on these results from IOCT analysis, and the spatiotemporal response of tumor-reactive T cells in the Cancer-Immunity Cycle, we speculate that anti-CD4 mAb treatment enhanced the expansion of a broad spectrum of tumor-reactive CD8+ T cell clones in the dLN and their translocation to the tumor via PBL (Figure 7C). The gene discussed is CD8A; the disease is cancer.